Imagine a world where the deadliest gynecological cancer could be prevented with a simple surgical tweak. That world is closer than you think. A groundbreaking Canadian innovation, born in British Columbia, is slashing the risk of ovarian cancer by a staggering 78%. But here's where it gets even more fascinating: this life-saving technique, known as opportunistic salpingectomy (OS), involves removing the fallopian tubes during routine gynecological surgeries like hysterectomies or tubal ligations. Sounds straightforward, right? But here's where it gets controversial: should this procedure become the new standard, or are there hidden risks we're not considering? Let’s dive in.
In 2010, B.C. became the first place in the world to introduce OS, thanks to a pioneering team from UBC, BC Cancer, and Vancouver Coastal Health. Their insight? Most ovarian cancers actually start in the fallopian tubes, not the ovaries. By removing the tubes while leaving the ovaries intact, OS preserves hormone production, minimizing side effects. And this is the part most people miss: this procedure doesn’t just reduce cancer risk—it’s also cost-effective and doesn’t impact the age of menopause onset.
A new study published in JAMA Network Open (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.57267?guestAccessKey=b761765e-d009-4b90-bee6-e0c930b248c1&utmsource=forthemedia&utmmedium=referral&utmcampaign=ftmlinks&utmcontent=tfl&utmterm=020226) analyzed data from over 85,000 individuals who underwent gynecological surgeries in B.C. between 2008 and 2020. The results? Those who had OS were 78% less likely to develop serous ovarian cancer, the most common and deadly subtype. Even in the rare cases where cancer did occur, it was less aggressive. But here’s the question: if this procedure is so effective, why isn’t it standard practice everywhere?
Dr. Gillian Hanley, co-senior author of the study, puts it plainly: “This relatively simple change in surgical practice can have a profound and life-saving impact.” Dr. Dianne Miller, who initially developed OS, adds a powerful perspective: “If there’s one thing better than curing cancer, it’s never getting it in the first place.” Yet, despite its success, OS isn’t universally adopted. Globally, only 24 countries recommend it as a prevention strategy. Why the hesitation?
Since its introduction, OS has been embraced in B.C., with 80% of hysterectomies and tubal ligations now including fallopian tube removal. The province has even expanded its use to other abdominal and pelvic surgeries, thanks to support from the Government of B.C. and Doctors of BC. Dr. David Huntsman, another co-senior author, emphasizes the potential: “Not offering this surgical add-on may leave patients unnecessarily vulnerable to this cancer.”
Ovarian cancer is devastating, with approximately 3,100 Canadians diagnosed annually and 2,000 deaths each year. Without a reliable screening test, most cases are caught at advanced stages, limiting treatment options. OS offers a beacon of hope—a proactive measure that could prevent thousands of cases worldwide. But here’s the debate: should OS be mandatory for eligible patients, or should it remain a choice? Weigh in below.
This research, funded by organizations like the Canadian Institutes of Health Research and the BC Cancer Foundation, highlights the power of collaboration between researchers and clinicians. As Dr. Sharmila Anandasabapathy, Dean of UBC’s Faculty of Medicine, notes: “This is a powerful example of how UBC research is changing clinical practice worldwide and saving lives.”
So, what do you think? Is OS the future of ovarian cancer prevention, or are there valid concerns holding it back? Share your thoughts in the comments—let’s spark a conversation that could shape the future of healthcare.
